|
| Press Releases |
|
 |
|
| Wednesday, September 28, 2016 |
|
|
Eisai Submits Supplemental Application for Partial Label Change for Antiepileptic Drug Fycompa |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has submitted a supplemental application for its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel) proposing the inclusion in labelling of a description of use as monotherapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older to the U.S Food and Drug Administration (FDA) based on new FDA policy.
more info >> |
|
| Thursday, September 15, 2016 |
|
|
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced that its European regional headquarters Eisai Europe Ltd. has received license from the European Commission for anticancer agent Kisplyx in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy. more info >> |
|
| Friday, August 26, 2016 |
|
|
Anticancer Agent "Treakisym for Injection 100 mg" Approved in Japan for Additional Indication of Chronic Lymphocytic Leukemia |
| Eisai Co., Ltd. announced today that the anticancer agent TREAKISYM for Injection 100 mg (generic name: bendamustine hydrochloride, "TREAKISYM") has been approved in Japan for an additional indication of chronic lymphocytic leukemia. more info >> |
|
| Tuesday, August 23, 2016 |
|
|
Eisai to Launch Chocola BB Mouth Ulcer Repair Shot |
| Eisai Co., Ltd. announced today that it will launch "Chocola BB Mouth Ulcer Repair Shot"(Third-class OTC drug) for mouth ulcers in Japan on Thursday, August 25. more info >> |
|
| Monday, August 1, 2016 |
|
|
Eisai Presents Results of Additional Analysis of Phase III Study of Anticancer Agent Halaven at 14th JSMO Annual Meeting Plenary Session |
| Eisai Co., Ltd. announced today that the results of an additional analysis of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). more info >> |
|
|
Eisai and Mamorio to Jointly Develop "Me-MAMORIO" Tracking Tool to Support People With Dementia Going Out |
| Eisai Co., Ltd. and MAMORIO, Inc. announced today that they have entered into an agreement to collaborate on the development of the MeMAMORIO1 tracking tool to support people with dementia going out. more info >> |
|
| Friday, July 22, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indication for Anticancer Agent Lenvatinib in Combination with Everolimus for Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate in combination with everolimus. more info >> |
|
| Wednesday, July 20, 2016 |
|
|
U.S. FDA Approves BELVIQ XR, A Once-Daily Formulation of Lorcaserin for Chronic Weight Management |
| Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BELVIQ XR, a once-daily formulation of lorcaserin hydrochloride (generic name, U.S. brand name: BELVIQ) for chronic weight management. more info >> |
|
| Thursday, June 30, 2016 |
|
|
Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. more info >> |
|
| Monday, June 20, 2016 |
|
|
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease |
| AbbVie GK, Eisai Co., Ltd., and its subsidiary EA Pharma Co., Ltd. today announced the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF monoclonal antibody formulation, in patients with moderate or severe Crohn's disease who become less responsive to treatment with 40 mg every two weeks to double the dose to 80 mg every two weeks. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024 
Apr 30, 2024 19:40 HKT/SGT
|
|
|
Q2 Metals Announces Completion of Drill-Core Re-Evaluation for the Cisco Lithium Property, James Bay Territory, Quebec, Canada
Apr 30, 2024 19:09 HKT/SGT
|
|
|
Sumitomo Metal Mining and Mitsubishi Corporation to Participate in Kalgoorlie Nickel Project - Goongarrie Hub
Apr 30, 2024 19:08 JST
|
|
|
Hong Kong Gifts, printing and packaging, and licensing events foster cross-industry opportunities
Apr 30, 2024 18:00 HKT/SGT
|
|
|
Moolec Announces New Patent Granting in the United States for Molecular Farming Platform
Apr 30, 2024 18:00 HKT/SGT
|
|
|
DCCI fortifies stance for Malaysia's greatest show: Wins support from key government organisations
Apr 30, 2024 17:56 HKT/SGT
|
|
|
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Apr 30, 2024 18:00 JST
|
|
|
Wintermar Offshore (WINS:JK) Reports 1Q2024 Results
Apr 30, 2024 16:48 HKT/SGT
|
|
|
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
Apr 30, 2024 17:25 JST
|
|
|
SMEStreet Celebrates 10 Years of Serving Indian MSMEs
Apr 30, 2024 16:23 HKT/SGT
|
|
|
Rockbird media Presents HR Leaders & HR Tech Strategy Meeting 2024: 'Rehumanizing Work with Emerging Technologies' in Manila
Apr 30, 2024 16:20 HKT/SGT
|
|
|
Tex Cycle Partners with Evolusi Bersatu to Launch Sabah's First Integrated Scheduled Waste Management Facility
Apr 30, 2024 15:55 HKT/SGT
|
|
|
World Blockchain Summit: Pioneering Insights and Strategic Partnerships Ignite in Dubai
Apr 30, 2024 15:16 HKT/SGT
|
|
|
FTLife Pre-Announces Name Change to Chow Tai Fook Life Insurance Company Limited
Apr 30, 2024 15:15 HKT/SGT
|
|
|
INNIO Group's 2023 Sustainability Report: Progress in Implementing Corporate Sustainability Goals
Apr 30, 2024 15:12 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
